Valneva (VALN) said Tuesday the European Commission granted marketing authorization for the Ixchiq vaccine to prevent chikungunya in adolescents aged 12 and older.
The approval was based on data from a six-month Phase 3 study in Brazil, which showed that a single dose induced a high immune response in 99.1% of adolescents.
The company said Ixchiq is now approved for adults and adolescents in the European Union, alongside approvals in the US, UK, and Canada.
Shares of Valneva were up over 1% in recent trading.
Price: 6.79, Change: +0.08, Percent Change: +1.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.